Damora Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -21.1% | -21.1% | -20.3% |
| FY2021 | -44.1% | -44.1% | -42.3% |
| FY2022 | -99.8% | -99.8% | -84.2% |
| FY2023 | -118.6% | -118.6% | -100.3% |
| FY2024 | -135.4% | -135.4% | -125.1% |
| FY2025 | -87.3% | -87.3% | -80.5% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2020 | -21.1% | -21.1% | -20.3% |
| FY2021 | -44.1% | -44.1% | -42.3% |
| FY2022 | -99.8% | -99.8% | -84.2% |
| FY2023 | -118.6% | -118.6% | -100.3% |
| FY2024 | -135.4% | -135.4% | -125.1% |
| FY2025 | -87.3% | -87.3% | -80.5% |